Edgewise Therapeutics announced positive top-line results from the 12-week Phase 2 CIRRUS-HCM trial of EDG-7500, a novel oral drug for obstructive and nonobstructive hypertrophic cardiomyopathy (HCM). The data will be presented at the European Society of Cardiology Congress in August 2026, highlighting the drug's potential to improve heart relaxation and function in symptomatic HCM patients. This trial is part of a multi-part study evaluating safety, efficacy, and dosing of EDG-7500, addressing a significant unmet need in treating this genetic heart disease that affects 1 in 500 people. The presentation will be available on Edgewise's website after the congress.
Ondas Holdings is valued similarly to established defense contractor AeroVironment despite much lower revenue and ongoing losses. AeroVironment reported $480.5 million revenue in Q1 2027 with strong backlog and profitability, while Ondas posted $83.8...
Bitmine now holds 6,016,414 ETH, about 4.9% of the total supply, and is 99% toward its goal of owning 5% of all Ethereum. It has staked over 5 million ETH, generating projected annual staking revenue of $363 million. Meanwhile, Strategy purchased 334...
AGCO Corporation has restructured its executive leadership, appointing Stefan Caspari as Senior Vice President and General Manager of Fendt/Valtra and Product Management. Caspari will also continue leading AGCO's North American agriculture business, ...
Panmure Liberum defends Plus500 after a sector sell-off triggered by IG Group's warning, maintaining a 'buy' rating and a 5,400p target. Plus500 confirmed trading in line with expectations for 2026 and holds a strong cash position, unlike IG whose re...
Gunnison Copper Corp has received pre-clearance to list on the NYSE American under the ticker "GUNN," allowing broader access for US investors. The company plans a Level II ADR program, with each ADR representing 35 common shares, expected to start t...
